• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Killing and regrowth of bacteria in vitro: a review.

作者信息

Craig W A, Ebert S C

机构信息

William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin.

出版信息

Scand J Infect Dis Suppl. 1990;74:63-70.

PMID:2097720
Abstract

Minimum inhibitory and bactericidal concentrations do not describe the time course of a drug's antimicrobial activity against bacteria. Some antimicrobials exhibit concentration dependent killing over a wide range of concentrations (e.g. aminoglycosides and quinolones), while others show maximal killing at concentrations near the MIC (e.g. beta-lactams and glycopeptides). The aminoglycosides and quinolones can require high drug concentrations (about 10-fold higher than the MIC) to prevent the selection of resistant subpopulations of bacteria. Persistent suppression of bacterial growth after antimicrobial exposure is called the 'postantibiotic effect' (PAE) and varies in duration depending on the drug-organism combination, as well as the concentration and duration of drug exposure. Antimicrobials which are inhibitors of protein and nucleic acid synthesis exhibit prolonged PAEs with a large variety of bacteria. While beta-lactam antibiotics demonstrate PAEs with Gram-positive cocci, very short or no PAEs are observed with these drugs with Gram-negative bacilli. The only exception is that penem antibiotics can induce PAEs with some strains of Gram-negative bacilli, primarily Pseudomonas aeruginosa. Thus, the pharmacodynamic activity of an antimicrobial can vary markedly depending on the microorganism and the class of drug and its concentration.

摘要

相似文献

1
Killing and regrowth of bacteria in vitro: a review.
Scand J Infect Dis Suppl. 1990;74:63-70.
2
The postantibiotic effect.抗生素后效应
Clin Pharm. 1992 Oct;11(10):865-75.
3
The postantibiotic effect induced by antimicrobial combinations.抗菌药物联合使用所诱导的抗生素后效应。
Scand J Infect Dis Suppl. 1990;74:80-93.
4
Pharmacodynamics of antimicrobial agents. Bactericidal and postantibiotic effects.抗菌药物的药效学。杀菌作用及抗生素后效应。
Infect Dis Clin North Am. 1995 Sep;9(3):483-95.
5
Post-antibiotic effect of three quinolones against gram negative isolates from urine.
Med Lab Sci. 1990 Oct;47(4):272-7.
6
Polyamine effects on antibiotic susceptibility in bacteria.多胺对细菌抗生素敏感性的影响。
Antimicrob Agents Chemother. 2007 Jun;51(6):2070-7. doi: 10.1128/AAC.01472-06. Epub 2007 Apr 16.
7
Synergic activity of beta-lactamines and aminoglycosides vs. bacterial strains treated with sub-MIC concentrations.β-内酰胺类和氨基糖苷类对亚抑菌浓度处理的细菌菌株的协同活性。
Chemioterapia. 1984 Jun;3(3):175-7.
8
Pharmacodynamic effects of antibiotics. Studies on bacterial morphology, initial killing, postantibiotic effect and effective regrowth time.抗生素的药效学效应。关于细菌形态、初始杀菌、抗生素后效应及有效再生长时间的研究。
Scand J Infect Dis Suppl. 1992;81:1-52. doi: 10.3109/inf.1992.24.suppl-81.01.
9
In vitro activity of MSI-78 alone and in combination with antibiotics against bacteria responsible for bloodstream infections in neutropenic patients.MSI-78单独及与抗生素联合应用对中性粒细胞减少患者血流感染病原菌的体外活性。
Int J Antimicrob Agents. 2005 Sep;26(3):235-40. doi: 10.1016/j.ijantimicag.2005.06.011.
10
The postantibiotic effect: a review of in vitro and in vivo data.抗生素后效应:体外和体内数据综述
DICP. 1991 Feb;25(2):153-63. doi: 10.1177/106002809102500210.

引用本文的文献

1
The evolution of heteroresistance via small colony variants in Escherichia coli following long term exposure to bacteriostatic antibiotics.大肠杆菌经长期抑菌抗生素处理后,通过小菌落变异体进化产生异质性耐药性。
Nat Commun. 2024 Sep 11;15(1):7936. doi: 10.1038/s41467-024-52166-z.
2
Antibiotics in anesthesia and critical care.麻醉与重症监护中的抗生素
Ann Transl Med. 2024 Feb 1;12(1):6. doi: 10.21037/atm-22-5585. Epub 2023 Dec 13.
3
Impact of Various Estimated Glomerular Filtration Rate Equations on the Pharmacokinetics of Meropenem in Critically Ill Adults.
不同肾小球滤过率估算方程对美罗培南在重症成人患者中药代动力学的影响
Crit Care Explor. 2023 Dec 14;5(12):e1011. doi: 10.1097/CCE.0000000000001011. eCollection 2023 Dec.
4
Utilizing Ceftazidime/Avibactam Therapeutic Drug Monitoring in the Treatment of Neurosurgical Meningitis Caused by Difficult-to-Treat Resistant and KPC-Producing Enterobacterales.利用头孢他啶/阿维巴坦治疗药物监测来治疗由难治性耐药及产KPC的肠杆菌科细菌引起的神经外科脑膜炎
Open Forum Infect Dis. 2023 Oct 19;10(11):ofad507. doi: 10.1093/ofid/ofad507. eCollection 2023 Nov.
5
The Evolution of Heteroresistance via Small Colony Variants in Following Long Term Exposure to Bacteriostatic Antibiotics.长期暴露于抑菌性抗生素后通过小菌落变体产生异质性耐药的演变
bioRxiv. 2024 Aug 23:2023.10.30.564761. doi: 10.1101/2023.10.30.564761.
6
The clinical application of beta-lactam antibiotic therapeutic drug monitoring in the critical care setting.β-内酰胺类抗生素治疗药物监测在重症监护环境中的临床应用。
J Antimicrob Chemother. 2023 Oct 3;78(10):2395-2405. doi: 10.1093/jac/dkad223.
7
Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients.新型β-内酰胺/β-内酰胺酶抑制剂组合及头孢地尔在重症患者中应用的理论依据与证据
Ann Intensive Care. 2023 Jul 18;13(1):65. doi: 10.1186/s13613-023-01153-6.
8
Beta-Lactam Dose Optimisation in the Intensive Care Unit: Targets, Therapeutic Drug Monitoring and Toxicity.重症监护病房中β-内酰胺类药物剂量优化:目标、治疗药物监测与毒性
Antibiotics (Basel). 2023 May 8;12(5):870. doi: 10.3390/antibiotics12050870.
9
Cefepime Dosing in a Critically Ill Neonate Receiving Continuous Renal Replacement Therapy With the Cardio-Renal Pediatric Dialysis Emergency Machine (CARPEDIEM).在使用心肺肾儿科透析急救机器(CARPEDIEM)进行持续肾脏替代治疗的危重新生儿中头孢吡肟的给药剂量。
J Pediatr Pharmacol Ther. 2023;28(2):167-171. doi: 10.5863/1551-6776-28.2.167. Epub 2023 Apr 26.
10
The Blood-Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults.血脑屏障与治疗成人中枢神经系统感染抗生素的药代动力学/药效学优化
Antibiotics (Basel). 2022 Dec 19;11(12):1843. doi: 10.3390/antibiotics11121843.